Stock of Interest (NWBO): Potentially Lose $0.5 or Gain $30 or More in Near Future

GlobeCitizen

新手上路
注册
2012-07-14
消息
133
荣誉分数
12
声望点数
28
While we are waiting for the topline data to be released "soon," relax and listen to the US Democratic presidential candidate Andrew Yang's interview with former Obama presidential campaign manager David Axelrod, which is a very inspirational and information rich podcast about Andrew and his campaign. Andrew has made history for all the Asians living in the US, and Canada as well in a not so direct manner, and of course in the US history. Regardless how far he can go in the future, he has become a model for all as a kind, caring, problem-solving, and forward looking thinker. so enjoy!
https://luminarypodcasts.com/listen...rew-yang/a54d79e7-d745-432d-a8d1-26cb49d791fd
 

GlobeCitizen

新手上路
注册
2012-07-14
消息
133
荣誉分数
12
声望点数
28
The long years of never-ending waiting and suffering manifested with this pure beauty of Tchaikovsky's Andante:

And maybe finally we are approaching the end of trial and also the beginning of prosperity embodied in this piece of beauty of Sarasate's Zigeunerweisen, full of melancholy and HOPE :
 

GlobeCitizen

新手上路
注册
2012-07-14
消息
133
荣誉分数
12
声望点数
28
Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management TeamPress Release | 12/12/2019
Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management Team
Executive With Decades of Public and Private Company Experience Joins NW Bio As CFO
PR Newswire

BETHESDA, Md., Dec. 12, 2019

BETHESDA, Md., Dec. 12, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has further expanded its senior management team with the addition of Ms. Jean M. Davis as Chief Financial Officer, Chief Accounting Officer, and interim Chief Information Officer.



Ms. Davis comes to NW Bio from BDO USA LLP, where she was a Risk Advisory Senior Manager. She is a Certified Public Accountant, Certified Sarbanes-Oxley Expert, Certified Internal Auditor, and Certified Project Management Professional. She obtained her Master of Science in Business with a concentration in Finance and Accounting from Johns Hopkins University.

Ms. Davis brings over 24 years of experience assisting both national and multi-national, public and private companies with their finance and accounting functions, financial reporting, compliance with financial, industry-specific and federal regulations, and related matters. Ms. Davis also worked previously at Deloitte & Touche.

"We are delighted to welcome Ms. Davis to NW Bio," commented NW Bio's CEO, Linda Powers. "We believe that her breath of knowledge and experience in finance and accounting, project management, data analytics and information technology, as well as her passion for our cause with DCVax®, will make Ms. Davis a strong addition to the NW Bio executive team."

Ms. Davis commented: "NW Bio is pursuing an exciting cause with its novel DCVax® immune therapies for cancer. I look forward to bringing my background and experience to bear to help take the Company to the next level.

About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is also pursuing development of DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial, and is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
 

GlobeCitizen

新手上路
注册
2012-07-14
消息
133
荣誉分数
12
声望点数
28

GlobeCitizen

新手上路
注册
2012-07-14
消息
133
荣誉分数
12
声望点数
28
Finally shareholder annual meeting date is set. Bought a lot of more shares recently and today. Please do your DD before commit anything.

NW Bio Announces Annual Shareholders' Meeting Scheduled for April 18, 2020Press Release | 02/18/2020
NW Bio Announces Annual Shareholders' Meeting Scheduled for April 18, 2020
PR Newswire
BETHESDA, Md., Feb. 18, 2020
BETHESDA, Md., Feb. 18, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the 2019 Annual Shareholder's Meeting will be held on April 18, 2020, at 1:00 pm in Washington, DC.

Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)

The Company encourages shareholders to attend what should be an interesting meeting. This announcement is being made to allow shareholders time to make necessary travel plans to come to Washington. The proxy information and other materials will be forwarded to shareholders in an official mailing at a later date.
The Company looks forward to seeing all who can attend.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is also developing DCVax®-Direct for all types of inoperable solid tumor cancers. The Company has completed a 40-patient Phase I trial, and is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax®-L for metastatic ovarian cancer together with the University of Pennsylvania.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ongoing ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing and expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
CONTACTS
Dave Innes Les Goldman
804-513-4758 dinnes@nwbio.com 240-234-0059 lgoldman@nwbio.com


Cision
View original content to download multimedia:NW Bio Announces Annual Shareholders' Meeting Scheduled for April 18, 2020
SOURCE Northwest Biotherapeutics
 

GlobeCitizen

新手上路
注册
2012-07-14
消息
133
荣誉分数
12
声望点数
28
Look at how a simple PR about a shareholder meeting that encourages shareholders to attend, gives a unprecedentedly long 60 days of time for travel arrangement and hints the meeting should be interesting can do, the price having increased more than 90% in a few days. Imaging if a real positive news is announced anytime before or on 18 April, what will that do to the price.

Anyhow, nothing will be fundamentally important except TLD announcement with the data up to the level of FDA approval.

Only until then, can the share price be close to its due price.
 

GlobeCitizen

新手上路
注册
2012-07-14
消息
133
荣誉分数
12
声望点数
28

NW Bio To Discuss Projected Schedule For Data Lock, Unblinding and Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting

PR Newswire

BETHESDA, Md., April 18, 2020

BETHESDA, Md., April 18, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its CEO, Linda Powers, will discuss the projected schedule for reaching data lock, unblinding and reporting of top line data from its 331-patient Phase 3 trial of DCVax®-L for Glioblastoma brain cancer at the Company's 2019 Annual Meeting. The Meeting is being held virtually due to the current public health crisis.

Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)

The Company has been working since last year with the contract research organization (CRO) that managed the trial and numerous independent service companies to make the final in-person monitoring visits to all the clinical trial sites (hospitals) across the US and Europe, and to finish collecting and confirming the Phase 3 trial data and resolving queries.

Despite nearly two months (during March and April to date) in which hospital trial sites stopped allowing in-person data monitoring visits and became too overwhelmed to continue helping with data confirmation, the Company's data collection and confirmation process has continued moving forward in part through workarounds.

The data collection process is including certain epigenetic and genetic information that is recognized as important in Glioblastoma, such as MGMT methylation status. As part of this process, the Company has also identified a method that can potentially enable an additional important genetic factor -- IDH mutation status -- to be analyzed using bio samples collected years ago during the trial, and to be analyzed in the same timeframe as the data lock. This IDH mutation factor was unknown when the Company's trial began and through much of the trial period, but has become recognized as very important in recent years.

After factoring in the March and April shutdowns, and the additional genetic analysis, the Company believes it can reach data lock by approximately the end of May.

Upon reaching data lock, the data will be unblinded to the independent statisticians (i.e., the statisticians will be given access to the trial database containing all of the raw data points). The Company will not yet become unblinded at this time.

The independent statisticians will then use the raw data to calculate the relevant measures, such as median survival times and survival percentages at various time points. The statisticians will also calculate various statistical measures and prepare graphs and tables. This work is anticipated to take several weeks. The Company will become unblinded when it receives these results from the statisticians.

The Company will then discuss the information from the statisticians with its expert advisors, including its Scientific Advisory Board and the Steering Committee of the Phase 3 trial. Any questions or comments raised by the experts will be addressed and the results will be prepared for public announcement.

Based on these expectations, and taking account of the two months lost in March and April, the current estimate of public disclosure of top line data would range from the end of June to early July.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is also pursuing development of DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial, and is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

CONTACTS

Dave Innes


Les Goldman

804-513-4758 dinnes@nwbio.com


240-234-0059 lgoldman@nwbio.com
 

GlobeCitizen

新手上路
注册
2012-07-14
消息
133
荣誉分数
12
声望点数
28

GlobeCitizen

新手上路
注册
2012-07-14
消息
133
荣誉分数
12
声望点数
28
It's been on the run-up finally. Some posts on Ihub:

"Dan88, Sunday, 05/17/20 03:06:01 PM, Post # of 284179

Reading this board is depressed if one is serious about it. It constantly generates misinformation and illogical opinions which tends to tear down any word or statement from the company/company official. I am not talking about the wolfpack, which I despise enough to not response, but some seemingly genuine longs. In their minds anything is suspicious and the result of yet one more conspiracy.

These seemingly longs and the wolfpack forms a perfect pair we have to face in a foreseeable future.

For instance, it's nothing wrong by Les saying the top 100 patients in the trial out of a total of 331 patients lived about 5 years. He was not talking about median OS, or HR or K-M curve about the trial and patients. He was talking to a general audience in a term most would understand better, and in a limited window of a few minute time.

He said it perfectly in the radio. When the top 100 patients lived or are living in a range from 4 years up to 9 years, it's correct to say those 100 patients lived/are living about 5 year, kind of the point around which the vast majority of those 100 patients lived or are living. Is anything wrong with that? For those whose thinking is always in confusion and conspiracy, it definitely is unfortunately.

It is a promotion, yes, but a deception? no, absolutely not. If an individual in the audience invests in the company as a result of listening to Les's few-minute radio promotion without doing any further DD, he/she deserves what is to come, either rake huge profit (dumb luck) or endure more than 50% drop ("deceived by Les") depending on the outcome of the trial.

Rest your brains, LOL at increasingly useless Wolfpack posting in this board. A change is in the making which nobody can stop!

[happy about the restriction on my posting. That means no response from me] "

"
Dan88, Thursday, 05/21/20 09:31:16 AM, Post # of 284195

What this board needs, as if I care, is a God sent psychologist to help those ever wandering to understand

Why some people say Yester's 8k is a non event? Like someone pretends to hold a long position?

And there will be no short squeeze in case with positive topline? Like a exwannabe?

And that if today's share price is not significantly higher, then the notion of short squeeze above is a bust? like a constant fliper flopper?

And a reduction of huge share counts will be no good because nobody cares, because Linda is a bad CEO? Like someone drinking Scotch?

Those people post day in and out and claims they don't have even a single share!

Lastly, if you are one of those who naked shorted with now useless warrants as hedge, what are you going to do today?

Panic to show weakness, so that everybody even a dumb cow will understand?

No, they will pretend, but the time is numbered!

It's laughable our wannebe friend thinks he can hold and carry a several dozen of millions in deficit account for six months, waiting for his future warrants to balance his ugly account. See how smart are those wolfpack hackers!

Believe or not, a huge short squeeze is coming!"


"
Dan88, Friday, 05/22/20 08:18:56 AM, Post # of 284185

Dreaming. With the same dreaming, many have missed $0.16, $0.17, and then $0.18, and then $0.19 ...while I have been buying.

Thing has changed. A potential financing is now a nothing burger in the face of huge potential realization within a short span of time.

It's called dynamic change or change of trend. Always be aware:

Today, before market open: nwbo stock market cap: $150 million, stock price: $0.24, with both numbers trending up for many days now, even with the numbers doubled or tripled it's still unbelievably cheap.

Because, the binary event is coming by the end of June or early July following data lock by the end of this month.

Borrowed a line from somebody else, it's still not too late to get in for a huge profit, or it's never too late to get in a paradigm shift stock.

It's your money, but I just hate to see long-term investors in a sour mood when we are so close to the final realization."
 
最后编辑:

GlobeCitizen

新手上路
注册
2012-07-14
消息
133
荣誉分数
12
声望点数
28
Now listen to this beautiful piece while in waiting:

 

GlobeCitizen

新手上路
注册
2012-07-14
消息
133
荣誉分数
12
声望点数
28
"

Dan88 Wednesday, 05/13/20 11:41:25 PM
Re: alphapuppy post# 282519
0
Post # of 284545


I share the same sentiment and anger you conveyed. If there is any truth in the setting though, the company must proceed as planned: Data Lock by end of May, Topline Data by early July, and the data must be reasonably positive or approval worthy.

Then, as share price rises significantly, a squeeze can still happen since those large numbers of warrants cannot be exercised before Nov, leaving previously hedged shares in effect naked, and no holders of these shares, now naked, would wait until Nov warrant exercise and share paying back, because nobody knows what would be happen in between in terms of share price, and the holders have books to balance.

Then, there will be lots of margin calls, and forced covering, propelling share price further higher.

Nonetheless, if those warrant holders, now realize their previously warrant hedged shares have become naked, start to cover in a significant way in the next several weeks before topline data announcement by early July, then it will be hard to see any squeeze after topline data announcement.
"

Either way share price will appreciate substantially, with the former much higher.

Even if there will be no significant squeeze, share price will definitely go up significantly with good data. So in this sense the interest of Linda and ours are still aligned.

BTW, it seems the company is still on track according to my inquiry to Dave and his answer, and also Umibe's conversation with Les.
 

GlobeCitizen

新手上路
注册
2012-07-14
消息
133
荣誉分数
12
声望点数
28
This young man KIPK in ihub has a good perspective of the macro-impact of the potentially successful DCVax platform:


KIPK Monday, 05/25/20 09:36:55 AM
Re: None
0
Post # of 284942


Many posters here underestimate the value of NWBO when they report their anticipated positive P3 Trial...

Medicine has been developed primarily from profit perspective & as such, formulations into means (pills..engineered cells...& etc...) that can be out into a bottle & prescribed....

This model of packaged Meds have made billions for big pharms...but its impact on disease therapy, PARTICULARLY, in Oncology has been totally limited...

In US, if the cost of a given therapy is $1 per use, the cost of treating the meds' side effects are $1.8 per use....Making the BP massive income, while the user gets worse for using it...

This lack of true Health Care Vs the actual Disease Care that we are currently in, it not a working model anymore ....

AND as a result of continuing failure of the system, THE HUMANITY as a whole is waking up and demanding for alternative Approaches That Are In line With What Nature (our Immune System) is offering us on minute to minute basis (otherwise we would have gone extinct long ago)..

From an Oncology perspective...NWBO technologies, represent a TRUE/natural approach that is based on stimulating the immune system in its totality (as opposed to those classified as Immunotherapy that are based on antibody use)...

With its anticipated success, NWBO therapy will undoubtedly threaten the use of current approaches & as such, minimize their popularity, profitability, & use...

The big pharma giants have known this for a while & have known know that access to meaningful alternative with no safety (side effects) concerns is UNAVOIDABLE...The Time Has Come...

This is the arena that NWBO has been plying in for many years, and no other company is even close enough to participate for years to come (IP Protections, time value,...cost..)...

This bring us to the fact that the competing Big Pharmas are all looking to Upgrade their therapeutic offerings & stay in the game if they want to survive...

The Kite/Juno/Engineered CAR-T are not even close (IMO) to be compared with the broadly applicable natural immuno-activating therapeutic platforms that NWBO has to offer...

Long NWBO...
 
顶部